UCB and Dermira Announce U.S. and EU Regulatory Submissions for CIMZIA® (certolizumab pegol) for the treatment of Moderate-to-Severe Chronic Plaque Psoriasis
UCB’s anti-epileptic drug VIMPAT® (lacosamide) receives EU CHMP positive opinion for both monotherapy and adjunctive therapy in children aged 4 years and older with epilepsy
Results from CRIB study on CIMZIA® (certolizumab pegol) demonstrate minimal to no placental transfer of drug from mother to infant during third trimester of pregnancy
New UCB data demonstrates scientific innovation for immunology patients with high unmet needs at the Annual European Congress of Rheumatology (EULAR) 2017